|
|
Article: Special Feature: Current Management of Rh and Kell Sensitization.
- Article from:
- OB/GYN Clinical Alert
- Article date:
- May 1, 2002
CopyrightCOPYRIGHT 2002 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Special Feature: Current Management of Rh and Kell Sensitization
By John C. Hobbins, MD
Since the advent of anti d immune globulin, the incidence of Rh sensitization and, consequently, erythroblastosis fetalis has plummetedbut not to zero. We generally are following 2 or 3 patients a month who are either Kell or Rh sensitized as a result of insufficient or ill-timed delivery of anti-immune globulin or mismatched transfusions.
Some recent developments have allowed a kinder, less invasive approach to management of these patients. The old way, unfortunately still used by some clinicians in the United States, was to perform antibody testing monthly ...